参考文献/References:
[1] Dong L,Cao Y,Hou Y,et al. N6-methyladenosine RNA methylation:A novel regulator of the development and function of immune cells[J]. J Cell Physiol,2022,237(1):329-345.
[2] Tsao CW,Aday AW,Almarzooq ZI,et al. Heart disease and Stroke Statistics-2023 Update:A report from the American Heart Association[J]. Circulation,2023,147(8):e93-e621.
[3] Sendinc E,Shi Y. RNA m6A methylation across the transcriptome[J]. Mol Cell,2023,83(3):428-441.
[4] Jiang X,Liu B,Nie Z,et al. The role of m6A modification in the biological functions and diseases[J]. Signal Transduct Target Ther,2021,6(1):74.
[5] Li L,Xu N,Liu J,et al. m6A methylation in cardiovascular diseases:from mechanisms to therapeutic potential[J]. Front Genet,2022,13:908976.
[6] Oerum S,Meynier V,Catala M,et al. A comprehensive review of m6A/m6Am RNA methyltransferase structures[J]. Nucleic Acids Res,2021,49(13):7239-7255.
[7] Bj?rkegren JLM,Lusis AJ. Atherosclerosis:recent developments[J]. Cell,2022,185(10):1630-1645.
[8] Kowara M,Cudnoch-jedrzejewska A. Pathophysiology of atherosclerotic plaque development-contemporary experience and new directions in research[J]. Int J Mol Sci,2021,22(7):3513.
[9] Xiong X,Hou L,Park YP,et al. Genetic drivers of m6A methylation in human brain,lung,heart and muscle[J]. Nat Genet,2021,53(8):1156-1165.
[10] Sun Y,Cheng Z,Cui M,et al. GAS5/METTL14/ESR1 genetic variants are related to the susceptibility of coronary heart disease[J]. Funct Integr Genomics,2022,22(3):341-357.
[11] Guo F,He M,Hu B,et al. Levels and clinical significance of the m6A methyltransferase METTL14 in patients with coronary heart disease[J]. Front Cardiovasc Med,2023,10:1167132.
[12] Jian D,Wang Y,Jian L,et al. METTL14 aggravates endothelial inflammation and atherosclerosis by increasing FOXO1 N6-methyladeosine modifications[J]. Theranostics,2020,10(20):8939-8956.
[13] Gao F,Kataoka M,Liu N,et al. Therapeutic role of miR-19a/19b in cardiac regeneration and protection from myocardial infarction[J]. Nat Commun,2019,10(1):1802.
[14] Zhang BY,Han L,Tang YF,et al. METTL14 regulates M6A methylation-modified primary miR-19a to promote cardiovascular endothelial cell proliferation and invasion[J]. Eur Rev Med Pharmacol Sci,2020,24(12):7015-7023.
[15] Yang Q,Chen S,Wang X,et al. Exercise mitigates endothelial pyroptosis and atherosclerosis by downregulating NEAT1 through N6-methyladenosine modifications[J]. Arterioscler Thromb Vasc Biol,2023,43(6):910-926.
[16] Min XL,Lin SX,Zhao XH,et al. Mechanisms of METTL14-Mediated m6A modification in promoting iron overload-induced lipid peroxidative damage in vascular endothelial cells to aggravate atherosclerosis[J]. J Biochem Mol Toxicol,2024,38(12):e70066.
[17] Kang P,Dong P. CircMETTL14(11)S upregulated METTL14 and induced CXCR4 to aggravate endothelial inflammation and atherosclerosis[J]. Int Immunopharmacol,2024,126:110979.
[18] Tang X,Yin R,Shi H,et al. LncRNA ZFAS1 confers inflammatory responses and reduces cholesterol efflux in atherosclerosis through regulating miR-654-3p-ADAM10/RAB22A axis[J]. Int J Cardiol,2020,315:72-80.
[19] Gong C,Fan Y,Liu J. METTL14 mediated m6A modification to LncRNA ZFAS1/RAB22A:A novel therapeutic target for atherosclerosis[J]. Int J Cardiol,2021,328:177.
[20] LIU Y,LUO G,TANG Q,et al. Methyltransferase-like 14 silencing relieves the development of atherosclerosis via m(6)A modification of p65 mRNA [J]. Bioengineered,2022,13(5):11832-11843.
[21] Hu R,Wang MQ,Ni SH,et al. Salidroside ameliorates endothelial inflammation and oxidative stress by regulating the AMPK/NF-kappaB/NLRP3 signaling pathway in AGEs-induced HUVECs[J]. Eur J Pharmacol,2020,867:172797.
[22] Pan H,Ho SE,Xue C,et al. Atherosclerosis is a smooth muscle cell-driven tumor-like disease[J]. Circulation,2024,149(24):1885-1898.
[23] Yang X,Wang C,Zhu G,et al. METTL14/YTHDF1 axis-modified UCHL5 aggravates atherosclerosis by activating the NLRP3 inflammasome[J]. Exp Cell Res,2023,427(2):113587.
[24] Chen J,Ning Y,Zhang H,et al. METTL14-dependent m6A regulates vascular calcification induced by indoxyl sulfate[J]. Life Sci,2019,239:117034.
[25] Hou P,Fang J,Liu Z,et al. Macrophage polarization and metabolism in atherosclerosis[J]. Cell Death Dis,2023,14(10):691.
[26] Zheng Y,Li Y,Ran X,et al. Mettl14 mediates the inflammatory response of macrophages in atherosclerosis through the NF-kappaB/IL-6 signaling pathway[J]. Cell Mol Life Sci,2022,79(6):311.
[27] Park MH,Jeong E,Choudhury M. Mono-(2-Ethylhexyl)phthalate regulates cholesterol efflux via microRNAs regulated m6A RNA methylation[J]. Chem Res Toxicol,2020,33(2):461-469.
[28] Yu Z,Zheng X,Wang C,et al. The Traditional chinese medicine hua tuo zai zao wan alleviates atherosclerosis by deactivation of inflammatory macrophages[J]. Evid Based Complement Alternat Med,2022,2022:2200662.
[29] Wang X,Ding Y,Li R,et al. N6-methyladenosine of Spi2a attenuates inflammation and sepsis-associated myocardial dysfunction in mice[J]. Nat Commun,2023,14(1):1185.
[30] Zhu S,Wang K,Yu Z,et al. Pulsatile flow increases METTL14-induced m6A modification and attenuates septic cardiomyopathy:an experimental study[J]. Int J Surg,2024,110(7):4103-4115.
[31] Cui J,Wang X,Dong L,et al. Curcumin reduces myocardial ischemia-reperfusion injury,by increasing endogenous H2S levels and further modulating m6A[J]. Mol Biol Rep,2024,51(1):558.
[32] Pang P,Qu Z,Yu S,et al. Mettl14 attenuates cardiac ischemia/reperfusion injury by regulating wnt1/β-catenin signaling pathway[J]. Front Cell Dev Biol,2021,9:762853.
[33] Wang L,Wang J,Yu P,et al. METTL14 is required for exercise-induced cardiac hypertrophy and protects against myocardial ischemia-reperfusion injury[J]. Nat Commun,2022,13(1):6762.
[34] Zhao C,Li J. METTL14-mediated N6-methyladenosine modification induces the ferroptosis of hypoxia/reoxygenation-induced cardiomyocytes[J]. J Cardiothorac Surg,2024,19(1):265.
[35] Wu C,Chen Y,Wang Y,et al. The m6A methylation enzyme METTL14 regulates myocardial ischemia/reperfusion injury through the Akt/mTOR signaling pathway[J]. Mol Cell Biochem,2024,479(6):1391-1400.
[36] Du W,Huang Y,Chen X,et al. Discovery of a PROTAC degrader for METTL3-METTL14 complex[J]. Cell Chem Biol,2024,31(1):177-183.e17.
[37] Yankova E,Blackaby W,Albertella M,et al. Small-molecule inhibition of METTL3 as a strategy against myeloid leukaemia[J]. Nature,2021,593(7860):597-601.
[38] Huang B,Xie L,Ke M,et al. Programmed release METTL3-14 Inhibitor Microneedle Protects Myocardial Function by Reducing Drp1 m6A modification-mediated mitochondrial fission[J]. ACS Appl Mater Interfaces,2023,15(40):46583-46597.